¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"angiotensin converting enzyme inhibitor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • debrancher enzyme
    °¡ÁöÁ¦°ÅÈ¿¼Ò, Å»ºÐÁöÈ¿¼Ò
  • digestive enzyme
    ¼ÒÈ­È¿¼Ò
  • double-sandwich enzyme-linked immunosorbent assay
    °ãÈ¿¼Ò¸é¿ªÃøÁ¤(¹ý)
  • extracellular enzyme
    ¼¼Æ÷¿ÜÈ¿¼Ò
  • enzyme
    È¿¼Ò
  • enzyme activity
    È¿¼ÒȰ¼º, È¿¼ÒȰ¼ºµµ
  • enzyme assay
    È¿¼ÒÃøÁ¤
  • enzyme immunoassay
    È¿¼Ò¸é¿ªºÐ¼®(¹ý)
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦
  • enzyme labeled antibody
    È¿¼ÒÇ¥ÁöÇ×ü
  • enzyme labeling
    È¿¼ÒÇ¥Áö
  • enzyme modulator mediated immunoassay
    È¿¼ÒÁ¶Àý¸Å°³¸é¿ªºÐ¼®(¹ý)
  • enzyme precursor
    È¿¼ÒÀü±¸¹°Áú
  • enzyme-antibody conjugate
    È¿¼ÒÇ×üÁ¢ÇÕü
  • enzyme-antienzyme reaction
    È¿¼ÒÇ×È¿¼Ò¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • branching enzyme
    °¡ÁöÄ¡±âÈ¿¼Ò, ºÐÁöÈ¿¼Ò
  • enzyme-linked immunoelectrotransfer blot
    È¿¼Ò¸é¿ªÀÌÀû¹ý, È¿¼Ò¿¬°ü¸é¿ªÀü±âÀü´ÞÁ¡
  • constitutive enzyme
    ±âº»±¸¼ºÈ¿¼Ò
  • curdling enzyme
    ÀÀÀ¯È¿¼Ò
  • cytosolic enzyme
    ¼¼Æ÷ÁúÈ¿¼Ò
  • enzyme-antibody conjugate
    È¿¼ÒÇ×üÁ¢ÇÕü
  • debrancher enzyme
    °¡ÁöÁ¦°ÅÈ¿¼Ò
  • degumming enzyme
    ÇØ±³È¿¼Ò
  • diastatic enzyme
    ´çÈ­È¿¼Ò
  • digestive enzyme
    ¼ÒÈ­È¿¼Ò
  • enzyme
    È¿¼Ò
  • enzyme immunoassay
    È¿¼Ò¸é¿ªºÐ¼®(¹ý)
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦
  • enzyme labeling
    È¿¼ÒÇ¥Áö
  • enzyme precursor
    È¿¼ÒÀü±¸Ã¼
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • inter-alpha-trypsin inhibitor
    ÀÎÅÍ-¾ËÆÄ-Æ®¸³½Å ¾ïÁ¦Á¦
  • plasma thromboplastin inhibitor
    ÇöóÁ <Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¾ïÁ¦¹°Áú.
  • plasmin activation inhibitor
    Çö󽺹ÎȰ¼ºÈ­¾ïÁ¦Á¦(¡­üÀàõûùåäð¤ð¥)
  • protease inhibitor
    ´Ü¹éÁúºÐÇØÈ¿¼Ò¾ïÁ¦Á¦
  • reductase, 5-alpha-reductase inhibitor
    5a-ȯ¿øÈ¿¼Ò¾ïÁ¦Á¦(¡­ü½êªý£áÈåäð¤ð¥),5a-¸®´öÅ×À̽º¾ïÁ¦Á¦(¡­åäð¤ð¥)
  • ELISA => enzyme-linked immunosorbent assay
    ¿¤¶óÀÌÀÚ
  • EMMIA => enzyme modulator mediated immunoassay
    È¿¼ÒÁ¶Àý¸Å°³¸é¿ªÃøÁ¤
  • adaptive enzyme
    ÀûÀÀÈ¿¼Ò(îêëëý£áÈ).
  • allosteric enzyme
    ¾Ë·Î½ºÅ׸®È¿¼Ò(¡­ý£áÈ).
  • antibody, enzyme-labelled
    È¿¼ÒÇ¥ÁöÇ×ü
  • glycolytic enzyme
    ÇØ´çÈ¿¼Ò.
  • glycolytic enzyme
    ÇØ´çÈ¿¼Ò
  • heterogeneous enzyme immunoassay
    ºÒ±ÕÀÏ<--Áú>È¿¼Ò¸é¿ªÇÐÀûÃøÁ¤(¹ý)
  • homogeneous enzyme immunoassay
    ±ÕÁúÈ¿¼Ò¸é¿ªÃøÁ¤(¹ý)
  • induced enzyme
    À¯µµÈ¿¼Ò.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • corrosion inhibitor
    ºÎ½Ä¹æÁöÁ¦(¡­ÛÁò­ð¥).
  • fertility inhibitor
    ¼öÁ¤¾ïÁ¦Á¦.
  • growth inhibitor
    ¼ºÀå<¹ßÀ°>¾ïÁ¦¹°Áú.
  • inhibitor
    ¾ïÁ¦Á¦
  • inhibitor
    ¾ïÁ¦ÀÚ
  • inhibitor
    ÀúÁöÀÚ, ¾ïÁ¦ÀÚ, ¾ïÁ¦ÀÎÀÚ
  • inhibitor polymerization
    ÁßÇÕ¾ïÁ¦Á¦.
  • inhibitor sensitive esterase
    ¾ïÁ¦¹°Áú¹ÝÀÀ¿¡½ºÅ×¶ó¾ÆÁ¦.
  • insulinase inhibitor
    Àν¶¸®³ª¾ÆÁ¦ÀúÇØ¹°Áú, Àν¶¸°ºÐÇØÈ¿¼Ò¾ïÁ¦¹°Áú.
  • inter-alpha-trypsin inhibitor
    ÀÎÅÍ-¾ËÆÄ-Æ®¸³½Å ¾ïÁ¦Á¦
  • luteinization inhibitor
    Ȳüȭ ¾ïÁ¦Á¦
  • metabolic inhibitor
    ´ë»ç¾ïÁ¦Á¦.
  • metabolic inhibitor
    ´ë»çÀúÇØÁ¦.[¾à¸®]´ë»ç¾ïÁ¦Á¦.
  • mitotic inhibitor
    Çٺп­ÀúÁöÀÎÀÚ(ú·ÝÂæñîÁò­ ì×í­).
  • monoamine oxidase inhibitor
    ¸ð³ë¾Æ¹Î ¿Á½Ã´ÙÁ¦ ÀúÇØÁ¦.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • ambiquitous enzyme
    ¾çÁ¸È¿¼Ò(å»ðíý£áÈ)
  • amino acid activating enzyme
    ¾Æ¹Ì³ë»ê(ß«) Ȱ¼ºÈ­(üÀàõûù) È¿¼Ò(ý£áÈ)
  • amplifier enzyme
    ÁõÆøÈ¿¼Ò(ñòøëý£áÈ)
  • analogous enzyme variants
    À¯»çÈ¿¼Ò º¯ÀÌÇü(×¾ÞÄý£áÈܨì¶úþ)
  • anti-enzyme
    Ç×È¿¼Ò(ù÷ý£áÈ)Ç×ü(ù÷ô÷)
  • antitumor enzyme
    Ç×Á¾¾ç È¿¼Ò(ù÷ðþåËý£áÈ)
  • auxilliary enzyme
    º¸Á¶È¿¼Ò (ÜÍð¾ý£áÈ)
  • basal enzyme
    ±âÀúÈ¿¼Ò(Ðñî¼ý£áÈ)
  • bound enzyme
    °áÇÕÈ¿¼Ò(ý£áÈ)
  • branching enzyme
    "ºÐÁöÈ¿¼Ò(ÝÂò«ý£áÈ), °¡ÁöÄ¡±â È¿¼Ò(ý£áÈ)"
  • breakage-reunion enzyme
    Àý´ÜÀç°áÇÕ È¿¼Ò(ï·Ó¨î¢Ì¿ùêý£áÈ)
  • CCA-enzyme
    CCA È¿¼Ò(ý£áÈ)
  • citrate cleavage enzyme
    ½ÃÆ®¸£»êÀý´ÜÈ¿¼Ò(ï·Ó¨ý£áÈ)
  • cold-sensitive enzyme
    ³Ã¹Î°¨ È¿¼Ò(Ò²ÚÂÊïý£áÈ)
  • clod-stable enzyme
    ³Ã¾ÈÁ¤ È¿¼Ò(Ò²äÌïÒý£áÈ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PI first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;...
CE California encephalitis; cardiac enlargement; cardioesophageal; carotid endarterectomy; catamenial e...
ICE ice, compression, elevation; ichthyosis-cheek-eyebrow [syndrome]; immunochemical evaluation; interle...
AI accidental injury; accidentally incurred; adiposity index; aggregation index; allergy and immunology...
EIA electroimmunoassay; enzyme immunoassay; enzyme-linked immunosorbent assay; equine infectious anemia;...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CEI Converting enzyme inhibition
ECE ET converting enzyme
ECE Endothelin converting enzyme
ECE-1 Endothelin converting enzyme-1
CE I-converting enzyme
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lipolytic enzyme
    Áö¹æ ºÐÇØ È¿¼Ò
  • lysosomal enzyme
    ¸®¼ÒÁ» È¿¼Ò, ¿ëÇØ ¼Òü È¿¼Ò
  • microsomal enzyme
    ¹Ì¼Òü È¿¼Ò
  • microsomal enzyme system
    ¹Ì¼Òü È¿¼Ò°è
  • neural enzyme system
    ½Å°æ È¿¼Ò°è
  • pancreatic enzyme
    Ãé È¿¼Ò
    ÃéÀå¿¡¼­ ºÐºñµÇ´Â ź¼öÈ­¹°, Áö¹æ, ´Ü¹éÁúÀ» ºÐÇØÇÏ´Â È¿¼Ò.
  • periplasmic enzyme
    ¿øÇüÁú¸· ÁÖÀ§ °ø°£ È¿¼Ò
  • phosphorylating enzyme
    ÀλêÈ­ È¿¼Ò
  • proteolytic enzyme
    ´Ü¹é ºÐÇØ È¿¼Ò
    ´Ü¹é ºÐÇØ¸¦ ÃËÁøÇÏ´Â È¿¼Ò.
  • Q enzyme
    Å¥ È¿¼Ò
    Æ÷µµ´ç-1-ÀλêÀÇ 1,6-C¿¡ ÀÛ¿ëÇÏ¿© À̰ÍÀ» ÁßÈ­½ÃŰ´Â È¿¼Ò.
  • rate-limiting enzyme
    ¼Óµµ Á¶Àý È¿¼Ò
  • receptor destroying enzyme
    ¼ö¿ëü ÆÄ±« È¿¼Ò
    ¼ö¿ëü¸¦ ÆÄ±«ÇÏ¿© ÀûÇ÷±¸ÀÇ ¹ÙÀÌ·¯½º ¿ëÇ÷¿¡ ´ëÇÑ °¨¼ö¼ºÀ» ÀÒ¾î¹ö¸®°Ô ÇÏ´Â È¿¼Ò.
  • splitting enzyme
    ºÐÇÒ È¿¼Ò
  • Z-enzyme
    ÁîÀÌ È¿¼Ò
    º£Å¸-¾Æ¹Ð¶óÁ¦¿Í Çù·ÂÇÏ¿© ¾Æ¹Ð·ÎÁ¦ÀÇ ¿ÏÀü ºÐÇØ¸¦ ÀÏÀ¸Å²´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
mechanism-based inhibitor A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme.
Synonym: mechanism-based inhibitor.
(05 Mar 2000)
glucosidase inhibitor Agents such as acarbose which reduce gastrointestinal absorption of carbohydrates. This group of drugs has been known popularly as "starch blockers". They lower plasma glucose levels and tend to cause weight loss. A limiting side effect is flatulence.
(05 Mar 2000)
medication, ace-inhibitor Agents that inhibit ACE (angiotensin-converting enzyme), thereby acting as vasodilators (really as anti-vasoconstrictors), lightening the stress load on the heart.
(12 Dec 1998)
residual inhibitor A sound-generating device, worn in the ear, which inhibits or suppresses the sounds of tinnitus by masking, with a residual inhibitory effect when the device is turned off.
(05 Mar 2000)
respiratory inhibitor A compound that inhibits the respiratory chain.
Synonym: respiratory poison.
(05 Mar 2000)
cholinesterase inhibitor <pharmacology> These are substances which which act to inhibit acetylcholinesterase, the enzyme which breaks down acetylcholine and thus enhance and subsequently prevent transmission of nerve impulses from one nerve cell to another or to a muscle.
Examples include pyridostigmine, ambenonium and neostigmine.
(15 Jan 1998)
monoamine oxidase inhibitor <pharmacology> A drug that interferes with the action of monoamine oxidase, slowing the breakdown of certain neurotransmitters. Used in the treatment of depression.
Monoamine oxidase inhibitors are a group of antidepressant drugs that prevent the activity of the enzyme monoamine oxidase in the central nervous system (brain) thus affecting mood. The use of these medications is often restricted due to their severe side effects and drug (and food) interactions.
Examples include isocarboxazid, pargyline, selegiline, furazolidone and phenelzine.
Acronym: MAOI
(26 Mar 1998)
complement cytolysis inhibitor <protein> Vertebrate glycoprotein of uncertain function. Secreted as a 400 amino acid peptide, then cleaved to form two 200 amino acid peptides that are linked by a disulphide bridge.
Synonym: complement associated protein, complement cytolysis inhibitor, glycoprotein III.
(11 Jan 1998)
plasminogen activator inhibitor 1 <chemical> A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998)
plasminogen activator inhibitor 2 <chemical> Member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998)
cyclooxygenase inhibitor <pharmacology> Compounds or agents that combine with cyclooxygenase (prostaglandin-endoperoxide synthase) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.
(08 Mar 2000)
protease inhibitor A drug that binds to and blocks HIV protease from working, thus preventing the production of new infectious viral articles.
(09 Oct 1997)
proteinase inhibitor inducing factor See: PIIF.
(18 Nov 1997)
protein c inhibitor <chemical> A member of the serpin family of proteins that is found in plasma and urine. It is dependent on heparin and able to inhibit activated protein c, thrombin, kallikrein, and other serine proteinases.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998)
protein synthesis inhibitor Compounds which inhibit the synthesis of proteins. They are usually antibiotics or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the the a site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á